SEATTLE--(BUSINESS WIRE)--Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical trials of investigational 18F-CTT1057, a diagnostic PET imaging agent for prostate cancer. CTT1057 targets the biomarker, Prostate Specific Membrane Antigen (PSMA), which is over-expressed on most prostate cancer cells. Prior to licensing, CTT completed prostate cancer clinical trials of CTT1057 in adult males at University of California, San Francisco (UCSF), with encouraging safety and imaging results. Based on this clinical data, binding characteristics of the molecule, and solid patent protection, CTT1057 was licensed to AAA to undergo further development in the upcoming GuidePath and GuideView clinical studies.
“This licensing deal with AAA is an important collaboration for CTT and we are very excited to see CTT1057 moving forward as a potential new imaging agent for prostate cancer,” stated Dr. Beatrice Langton-Webster, CTT’s Chief Executive Officer. The milestone payments, along with an NIH SBIR Phase IIB grant, are the key assets that CTT is using to advance its new radiolabeled small molecule drug CTT1403, a companion radiotherapeutic to CTT1057. Features that make the phosphoramidate PSMA-binding scaffold unique include irreversible binding to PSMA and excellent uptake by PSMA-expressing tumor cells. CTT1057 and CTT1403 are a theranostic pair that can both diagnose and treat solid tumors that express PSMA and are being studied together in the current CTT1403 therapeutic clinical trial (NCT03822871) that CTT is conducting with lead investigator Dr. Rahul Aggarwal at UCSF. The unique chemical structures of CTT’s drugs were conceived by Dr. Cliff Berkman, Professor of Chemistry at Washington State University (WSU).
More information on the trials listed in this release can be found at clinicaltrials.gov.